Venus Remedies shots up on receiving DCGI nod to conduct Phase-111 clinical trials of cancer detection NCE

05 Dec 2012 Evaluate

Venus Remedies is currently trading at Rs. 317.60, up by 18.85 points or 6.31% from its previous closing of Rs. 298.75 on the BSE.

The scrip opened at Rs. 302.35 and has touched a high and low of Rs. 327.80 and Rs. 302.35 respectively. So far 2, 06,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 327.80 on 5-Dec-2012 and a 52 week low of Rs. 141.05 on 22-Dec-2011.

Last one week high and low of the scrip stood at Rs. 327.80 and Rs. 277.60 respectively. The current market cap of the company is Rs. 309 crore.

The promoters holding in the company stood at 34.21% while Institutions and Non-Institutions held 14.43% and 51.36% respectively.

Venus Remedies has received approval from Drugs Controller General, India (DCGI) to conduct Phase-111 clinical trials of its cancer detection new chemical entity (NCE). After thorough screening by IND committee for the investigational NCE VRP1620, DCGI has found Clinical Phase-1 and Phase-11 data satisfactory and thus granted permission to conduct Phase-111 clinical trials on the molecule. The molecule is for early cancer detection and this leap towards successful Phase-111 will make the company pioneers among the companies working and providing innovative solution for cancer detection.

Venus Remedies has presented positive results of the investigational NCE VRP1620 after completion of meticulously planned, managed, executed and analyzed two pivotal Phase-1 & Phase-11 clinical trials. The company is planning to launch this NCE by last quarter of 2013 in India for the first time globally.

Venus Remedies had successfully completed Phase-1 study at Postgraduate Institute of Medical Sciences (PGIMER) Chandigarh conducted to find maximum tolerable dose levels in breast cancer patients in third quarter of 2010. Later, in April 2011, after DCGI approval Phase-11 study of this molecule was conducted at multiple institutions throughout India including PGIMER, Chandigarh and Central India Cancer Research Institute, Nagpur, Maharashtra to establish the pharmacokinetic profile and preliminary efficacy of the drug.

Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.

Venus Remedies Share Price

745.20 -7.70 (-1.02%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×